CHF Drug Trial Standards Debated By Natrecor Advisory Committee
Executive Summary
If sponsors of acute congestive heart failure drug studies need to limit the patient population, they should focus on non-catheterized patients, FDA Cardio-Renal Drug Products Division Director Raymond Lipicky, MD, suggested during a May 25 advisory committee meeting.